China Still Alluring? AZ, Pfizer Feel COVID Pinch, New Pricing Scheme Clouds Outlook
Pandemic Impact Starts Surfacing
Executive Summary
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
You may also be interested in...
Some Companies Say 'No' To China's Latest VBP Round
Only three of 40 qualified international drug firms won in the latest round of China's central bidding process, showing a toughening environment. But some companies are seemingly determined not to lower prices any further.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.